Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Efficacy of lung cancer screening appears to increase with prolonged intervention: results from the MILD trial and a meta-analysis.

Rota M, Pizzato M, La Vecchia C, Boffetta P.

Ann Oncol. 2019 May 2. pii: mdz145. doi: 10.1093/annonc/mdz145. [Epub ahead of print] No abstract available.

PMID:
31046087
2.

The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists.

de Sousa-Pereira P, Abrantes J, Bauernfried S, Pierini V, Esteves PJ, Keppler OT, Pizzato M, Hornung V, Fackler OT, Baldauf HM.

J Gen Virol. 2019 Feb;100(2):278-288. doi: 10.1099/jgv.0.001201. Epub 2018 Dec 19.

PMID:
30566072
3.

SERINC5 as a New Restriction Factor for Human Immunodeficiency Virus and Murine Leukemia Virus.

Firrito C, Bertelli C, Vanzo T, Chande A, Pizzato M.

Annu Rev Virol. 2018 Sep 29;5(1):323-340. doi: 10.1146/annurev-virology-092917-043308. Review.

PMID:
30265629
4.

Mechanical activation of Efavirenz: the effects on the dissolution and inhibitory behavior.

Cappelletto E, Firrito C, Pizzato M, Rebuffi L, Scardi P.

Pharm Dev Technol. 2018 Dec;23(10):1128-1135. doi: 10.1080/10837450.2018.1469148. Epub 2018 May 8.

PMID:
29688125
5.

Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5.

Schulte B, Selyutina A, Opp S, Herschhorn A, Sodroski JG, Pizzato M, Diaz-Griffero F.

Virology. 2018 Feb;515:52-65. doi: 10.1016/j.virol.2017.12.005. Epub 2017 Dec 18.

6.

The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles.

Trautz B, Wiedemann H, Lüchtenborg C, Pierini V, Kranich J, Glass B, Kräusslich HG, Brocker T, Pizzato M, Ruggieri A, Brügger B, Fackler OT.

J Biol Chem. 2017 Aug 18;292(33):13702-13713. doi: 10.1074/jbc.M117.797332. Epub 2017 Jun 28.

7.

SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins.

Sood C, Marin M, Chande A, Pizzato M, Melikyan GB.

J Biol Chem. 2017 Apr 7;292(14):6014-6026. doi: 10.1074/jbc.M117.777714. Epub 2017 Feb 8.

8.

S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.

Chande A, Cuccurullo EC, Rosa A, Ziglio S, Carpenter S, Pizzato M.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13197-13202. Epub 2016 Nov 1.

9.

The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.

Trautz B, Pierini V, Wombacher R, Stolp B, Chase AJ, Pizzato M, Fackler OT.

J Virol. 2016 Nov 14;90(23):10915-10927. doi: 10.1128/JVI.01246-16. Print 2016 Dec 1.

10.

The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild.

Heigele A, Kmiec D, Regensburger K, Langer S, Peiffer L, Stürzel CM, Sauter D, Peeters M, Pizzato M, Learn GH, Hahn BH, Kirchhoff F.

Cell Host Microbe. 2016 Sep 14;20(3):381-391. doi: 10.1016/j.chom.2016.08.004.

11.

HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation.

Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, McCauley SM, Nowosielska A, Antonarakis SE, Luban J, Santoni FA, Pizzato M.

Nature. 2015 Oct 8;526(7572):212-7. doi: 10.1038/nature15399. Epub 2015 Sep 30.

12.

Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration.

Pizzato M, McCauley SM, Neagu MR, Pertel T, Firrito C, Ziglio S, Dauphin A, Zufferey M, Berthoux L, Luban J.

PLoS Pathog. 2015 Jul 16;11(7):e1005050. doi: 10.1371/journal.ppat.1005050. eCollection 2015 Jul.

13.

Galanin pathogenic mutations in temporal lobe epilepsy.

Guipponi M, Chentouf A, Webling KE, Freimann K, Crespel A, Nobile C, Lemke JR, Hansen J, Dorn T, Lesca G, Ryvlin P, Hirsch E, Rudolf G, Rosenberg DS, Weber Y, Becker F, Helbig I, Muhle H, Salzmann A, Chaouch M, Oubaiche ML, Ziglio S, Gehrig C, Santoni F, Pizzato M, Langel Ü, Antonarakis SE.

Hum Mol Genet. 2015 Jun 1;24(11):3082-91. doi: 10.1093/hmg/ddv060. Epub 2015 Feb 17.

PMID:
25691535
14.

Retroviral factors promoting infectivity.

Cuccurullo EC, Valentini C, Pizzato M.

Prog Mol Biol Transl Sci. 2015;129:213-51. doi: 10.1016/bs.pmbts.2014.10.008. Epub 2014 Dec 1. Review.

PMID:
25595806
15.

The activity of Nef on HIV-1 infectivity.

Basmaciogullari S, Pizzato M.

Front Microbiol. 2014 May 20;5:232. doi: 10.3389/fmicb.2014.00232. eCollection 2014. Review.

16.

Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors.

Vermeire J, Naessens E, Vanderstraeten H, Landi A, Iannucci V, Van Nuffel A, Taghon T, Pizzato M, Verhasselt B.

PLoS One. 2012;7(12):e50859. doi: 10.1371/journal.pone.0050859. Epub 2012 Dec 5.

17.

The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α.

Miyamoto T, Nakayama EE, Yokoyama M, Ibe S, Takehara S, Kono K, Yokomaku Y, Pizzato M, Luban J, Sugiura W, Sato H, Shioda T.

PLoS One. 2012;7(10):e47757. doi: 10.1371/journal.pone.0047757. Epub 2012 Oct 19.

18.

Fetal ductal constriction caused by maternal ingestion of green tea in late pregnancy: an experimental study.

Zielinsky P, Manica JL, Piccoli AL Jr, Nicoloso LH, Barra M, Alievi MM, Vian I, Zilio A, Pizzato PE, Silva JS, Bender LP, Pizzato M, Menezes HS, Garcia SC.

Prenat Diagn. 2012 Oct;32(10):921-6. doi: 10.1002/pd.3933. Epub 2012 Jul 23.

PMID:
22821626
19.

Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41.

Lai RP, Yan J, Heeney J, McClure MO, Göttlinger H, Luban J, Pizzato M.

PLoS Pathog. 2011 Dec;7(12):e1002442. doi: 10.1371/journal.ppat.1002442. Epub 2011 Dec 15.

20.

Reversal of fetal ductal constriction after maternal restriction of polyphenol-rich foods: an open clinical trial.

Zielinsky P, Piccoli AL Jr, Manica JL, Nicoloso LH, Vian I, Bender L, Pizzato P, Pizzato M, Swarowsky F, Barbisan C, Mello A, Garcia SC.

J Perinatol. 2012 Aug;32(8):574-9. doi: 10.1038/jp.2011.153. Epub 2011 Nov 3.

PMID:
22052330
21.

TRIM5 is an innate immune sensor for the retrovirus capsid lattice.

Pertel T, Hausmann S, Morger D, Züger S, Guerra J, Lascano J, Reinhard C, Santoni FA, Uchil PD, Chatel L, Bisiaux A, Albert ML, Strambio-De-Castillia C, Mothes W, Pizzato M, Grütter MG, Luban J.

Nature. 2011 Apr 21;472(7343):361-5. doi: 10.1038/nature09976.

22.

MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1.

Pizzato M.

Proc Natl Acad Sci U S A. 2010 May 18;107(20):9364-9. doi: 10.1073/pnas.1001554107. Epub 2010 May 3.

23.

Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions.

Sokolskaja E, Olivari S, Zufferey M, Strambio-De-Castillia C, Pizzato M, Luban J.

J Virol. 2010 May;84(9):4851-5. doi: 10.1128/JVI.01699-09. Epub 2010 Feb 24.

24.

A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants.

Pizzato M, Erlwein O, Bonsall D, Kaye S, Muir D, McClure MO.

J Virol Methods. 2009 Mar;156(1-2):1-7. doi: 10.1016/j.jviromet.2008.10.012. Epub 2008 Dec 5.

PMID:
19022294
25.

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research.

Takeuchi Y, McClure MO, Pizzato M.

J Virol. 2008 Dec;82(24):12585-8. doi: 10.1128/JVI.01726-08. Epub 2008 Oct 8.

26.

Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles.

Pizzato M, Popova E, Göttlinger HG.

J Virol. 2008 Nov;82(21):10811-9. doi: 10.1128/JVI.01150-08. Epub 2008 Aug 20.

27.

Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef.

Pizzato M, Helander A, Popova E, Calistri A, Zamborlini A, Palù G, Göttlinger HG.

Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6812-7. Epub 2007 Apr 5.

28.
29.
30.

Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection.

Walker SJ, Pizzato M, Takeuchi Y, Devereux S.

J Virol. 2002 Jul;76(14):6909-18.

31.

Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix.

Dorfman T, Popova E, Pizzato M, Göttlinger HG.

J Virol. 2002 Jul;76(13):6857-62.

32.

Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells.

Pizzato M, Blair ED, Fling M, Kopf J, Tomassetti A, Weiss RA, Takeuchi Y.

Gene Ther. 2001 Jul;8(14):1088-96.

33.

Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.

Pizzato M, Merten OW, Blair ED, Takeuchi Y.

Gene Ther. 2001 May;8(10):737-45. Erratum in: Gene Ther 2001 Oct;8(19):1514.

34.

Progress with retroviral gene vectors.

Palù G, Parolin C, Takeuchi Y, Pizzato M.

Rev Med Virol. 2000 May-Jun;10(3):185-202. Review.

PMID:
10815029
35.

Retrovirus vectors.

Takeuchi Y, Pizzato M.

Adv Exp Med Biol. 2000;465:23-35. Review. No abstract available.

PMID:
10810612
36.

Gene Therapy of Glioblastoma Multiforme with a Bicistronic Retroviral Vector Expressing Human IL-2 and HSV-tK.

Palù G, Pizzato M, Bonaguro R, Colombo F.

Methods Mol Med. 2000;35:511-22. doi: 10.1385/1-59259-086-1:511.

PMID:
21390827
37.
38.

Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans.

Palù G, Cavaggioni A, Calvi P, Franchin E, Pizzato M, Boschetto R, Parolin C, Chilosi M, Ferrini S, Zanusso A, Colombo F.

Gene Ther. 1999 Mar;6(3):330-7.

39.

Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping.

Calistri A, Parolin C, Pizzato M, Calvi P, Giaretta I, Palù G.

J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):90-8.

PMID:
10360799
40.
41.

Determination of HPRT mutant frequency and molecular analysis of T-lymphocyte mutants derived from coke-oven workers.

Zanesi N, Mognato M, Pizzato M, Viezzer C, Ferri G, Celotti L.

Mutat Res. 1998 Jan 30;412(2):177-86.

PMID:
9539972
42.

Effect of differential growth conditions on the dTTP pool size in herpes simplex virus-infected Vero cells.

Marcello A, Pizzato M, Loregian A, Palù G.

Biochem Soc Trans. 1995 Nov;23(4):627S. No abstract available.

PMID:
8654812
43.
44.

[Visual electrophysiology in 101 children with encephalopathy].

Le Gargasson JF, Rigaudiere F, Dufier JL, Aicardi J, Goutieres F, Pizzato M, Grall Y.

J Fr Ophtalmol. 1990;13(8-9):441-8. Review. French.

PMID:
2081856
45.

Data processing software for electrophysiological visual exploration.

Grall Y, Legargasson JF, Rigaudière F, Pizzato M.

Comput Methods Programs Biomed. 1989 Feb;28(2):101-9.

PMID:
2924553
46.

[Retinal protection using glasses filtering short wave lengths in patients with hereditary degenerative diseases. First electrophysiologic results].

Le Gargasson JF, Rigaudière F, Grall Y, Pizzato M, Keller J, Ingster-Moati I.

Ophtalmologie. 1989 Jan-Mar;3(1):65-6. French.

PMID:
2641074
47.

[Comparative statistical study of the visual evoked potentials in subjects suspected of having multiple sclerosis with and without ophthalmic signs].

Le Gargasson JF, Rigaudière F, Grall Y, Keller J, Ingster-Moati I, Pizzato M.

Ophtalmologie. 1988 Apr-Jun;2(2):161-6. French. No abstract available.

PMID:
3247155
48.

[A new look at Credé's method].

Da Poian VR, Louzada ML, Pizzato M.

Rev Gaucha Enferm. 1986 Jan;7(1):1-11. Portuguese. No abstract available.

PMID:
3538239
49.

Correlation functions in the analysis of visual evoked potentials.

Grall Y, Keller J, Boiteux Y, Legargasson JF, Pizzato M.

Doc Ophthalmol. 1985 Feb;59(2):149-55.

PMID:
3838932
50.

[Maintenance of oxygenation of the premature newborn infant].

Da Poian VR, Pizzato M.

Rev Gaucha Enferm. 1984 Jan;5(1):19-27. Portuguese. No abstract available.

PMID:
6570263

Supplemental Content

Loading ...
Support Center